Zobrazeno 1 - 10
of 248
pro vyhledávání: '"Odd Terje Brustugun"'
Autor:
Hanne Marte Nymoen, Tine Norman Alver, Henrik Horndalsveen, Hanne Astrid Eide, Maria Moksnes Bjaanæs, Odd Terje Brustugun, Bjørn Henning Grønberg, Vilde Drageset Haakensen, Åslaug Helland
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundRadiotherapy (RT) can be used to reduce symptoms and maintain open airways for patients with non-small cell lung cancer when systemic treatment is not sufficient. For some patients, tumor control is not achieved due to radioresistance. Conc
Externí odkaz:
https://doaj.org/article/e8ccea5765124b9cb6e2d11e1fe3772e
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Lars Fjellbirkeland, Åslaug Helland, Bjørn Møller, Sissel Gyrid Freim Wahl, Steinar Solberg
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The main focus on the characteristics of malignant lung tumours has been the size, position within the lobe, and infiltration into neighbouring structures. The aim of this study was to investigate the distribution and characterist
Externí odkaz:
https://doaj.org/article/5875a883bc094aa79f00eb35ae725d73
Autor:
Dan Lærum, Trond-Eirik Strand, Odd Terje Brustugun, Frode Gallefoss, Ragnhild Falk, Michael T. Durheim, Lars Fjellbirkeland
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Whether sex is an independent prognostic factor in lung cancer survival is the subject of ongoing debate. Both large national registries and single hospital studies have shown conflicting findings. In this study, we explore the impact of
Externí odkaz:
https://doaj.org/article/7c8d766c6204494fac73795780a3ffea
Autor:
Anne Pernille Harlem Dyrbekk, Abdirashid Ali Warsame, Pål Suhrke, Marianne Odnakk Ludahl, Joakim Oliu Moe, Inger Johanne Zwicky Eide, Marius Lund-Iversen, Odd Terje Brustugun
Publikováno v:
Diagnostic Pathology, Vol 18, Iss 1, Pp 1-13 (2023)
Abstract Background ROS1 fusion is an infrequent, but attractive target for therapy in patients with metastatic non- small-cell lung cancer. In studies on mainly late-stage disease, the prevalence of ROS1 fusions is about 1–3%. In early-stage lung
Externí odkaz:
https://doaj.org/article/36926be6be1c4199a84064f4db86b336
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Morten Tandberg Eriksen, Marianne G. Guren, Erik Skaaheim Haug, Bjørn Naume, Ellen Schlichting, Bjørn Møller
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Cancer patient pathways (CPPs) were implemented in Norway to reduce unnecessary waiting times, regional variations, and to increase the predictability of cancer care for the patients. This study aimed to determine if 70% of cancer
Externí odkaz:
https://doaj.org/article/f1e88728779a43d0803e29d8f28fd44c
Autor:
Maria Moksnes Bjaanæs, Gro Nilsen, Ann Rita Halvorsen, Hege G. Russnes, Steinar Solberg, Lars Jørgensen, Odd Terje Brustugun, Ole Christian Lingjærde, Åslaug Helland
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Genetic alterations are common in non-small cell lung cancer (NSCLC), and DNA mutations and translocations are targets for therapy. Copy number aberrations occur frequently in NSCLC tumors and may influence gene expression and fur
Externí odkaz:
https://doaj.org/article/b825e8f1773e4763ad45d7e3de7d52b8
Publikováno v:
Cancers, Vol 15, Iss 5, p 1505 (2023)
Clinical studies have shown the efficacy of EGFR- and ALK-directed therapies in non-small cell lung cancer (NSCLC). Real-world data on, e.g., testing patterns, uptake, and duration of treatment are scarce. Reflex EGFR and ALK testing of non-squamous
Externí odkaz:
https://doaj.org/article/f75aa772c6684ede95dd460776aa4086
Autor:
Anand Khadse, Vilde D. Haakensen, Laxmi Silwal-Pandit, Julian Hamfjord, Patrick Micke, Johan Botling, Odd Terje Brustugun, Ole Christian Lingjærde, Åslaug Helland, Elin H. Kure
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Lung cancer is a common disease with a poor prognosis. Genomic alterations involving the KRAS gene are common in lung carcinomas, although much is unknown about how different mutations, deletions, and expressions influence the disease course. The fir
Externí odkaz:
https://doaj.org/article/add8e489bc4c4fa9b31afcd0d783f3bf
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Morten Tandberg Eriksen, Erik Skaaheim Haug, Bjørn Naume, Bjørn Møller
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Cancer patient pathways (CPPs) were implemented in 2015 to reduce waiting time, regional variation in waiting time, and to increase the predictability of cancer care for the patients. The aims of this study were to see if the nati
Externí odkaz:
https://doaj.org/article/2a3b37da840644dab4f585cacbab58d8
Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
Autor:
Ann Rita Halvorsen, Miriam Ragle Aure, Åsa Kristina Õjlert, Odd Terje Brustugun, Steinar Solberg, Daniel Nebdal, Åslaug Helland
Publikováno v:
Molecular Oncology, Vol 13, Iss 12, Pp 2604-2615 (2019)
Dysregulation of microRNAs is a common mechanism in the development of lung cancer, but the relationship between microRNAs and expression subtypes in non‐small‐cell lung cancer (NSCLC) is poorly explored. Here, we analyzed microRNA expression fro
Externí odkaz:
https://doaj.org/article/e5a7cf1c8fd1450299033bf9b3e3fc6f